BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 7855784)

  • 1. High versus ultra-high purity factor VIII concentrate therapy: prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs.
    Varon D; Schulman S; Dardik R; Barzilai A; Bashari D; Martinowitz U
    Thromb Haemost; 1994 Sep; 72(3):359-62. PubMed ID: 7855784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4 cells in HIV-1 infected hemophiliacs: effect of factor VIII concentrates.
    Goldsmith JM; Deutsche J; Tang M; Green D
    Thromb Haemost; 1991 Oct; 66(4):415-9. PubMed ID: 1839091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate.
    Mannucci PM; Gringeri A; de Biasi R; Baudo F; Morfini M; Ciavarella N
    Thromb Haemost; 1992 Mar; 67(3):310-3. PubMed ID: 1353642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate.
    Allersma DP; Smid WM; van der Does JA; van der Meer J; Briët E
    Thromb Haemost; 1996 Feb; 75(2):261-6. PubMed ID: 8815573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients.
    Sabin C; Pasi J; Phillips A; Elford J; Janossy G; Lee C
    Thromb Haemost; 1994 Aug; 72(2):214-7. PubMed ID: 7831654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evolution of CD4 and CD8 lymphocyte subsets in HIV seronegative and seropositive hemophiliacs].
    Lorenzo JI; Molina R; Aznar JA
    Sangre (Barc); 1993 Feb; 38(1):5-11. PubMed ID: 8470035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of the type of factor VIII concentrate on the CD4 lymphocyte count in hemophiliacs with human immunodeficiency virus infection: the results of a meta-analysis].
    Montoro Ronsano JB; Oliveras Martín J; Tusell Puigbert JM
    Med Clin (Barc); 1994 Nov; 103(18):690-4. PubMed ID: 7808075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM
    Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of factor VIII concentrates of very high purity on CD4+ cell count in hemophiliacs infected with HIV].
    Molina Alejandro R; Lorenzo Herrero JI; Haya Guaita S; Querol Fuentes F; Aznar Lucea JA
    Rev Clin Esp; 1996 Jun; 196(6):365-9. PubMed ID: 8767071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The course of preexistent immune abnormalities in HIV negative haemophiliacs treated for two years with a monoclonal purified factor VIII concentrate.
    Smid WM; van der Meer J; Smit JW; Halie MR
    Thromb Haemost; 1993 Apr; 69(4):306-10. PubMed ID: 8388579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease of CD4 cell number and function in HIV-seropositive hemophiliacs in a longitudinal study.
    Knutsen AP; Bouhasin JD; Joist JH; Scrivner D; Mueller KR; Gioia K; Janney S
    Ann Allergy; 1989 Sep; 63(3):189-94. PubMed ID: 2528308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
    Seremetis SV
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical, immunological, and virological aspects in Japanese hemophiliacs and AIDS patients.
    Abe T
    AIDS Res; 1986 Dec; 2 Suppl 1():S141-6. PubMed ID: 3103637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral and cellular immune abnormalities in adult hemophiliacs followed over a 2-year period.
    Freedman J; Mazaheri R; Read S; Garvey MB; Teitel J
    Diagn Clin Immunol; 1987; 5(1):30-40. PubMed ID: 2439226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII concentrates in HIV-1-positive hemophiliacs--is pure better?
    Eichinger S; Pabinger I; Kyrle PA; Köller U; Kier P; Schneider B; Lechner K
    Haemostasis; 1992; 22(1):25-31. PubMed ID: 1521824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of antibodies to AIDS-associated retrovirus in in- and out-patients in Japan.
    Ikegami N
    AIDS Res; 1986 Dec; 2 Suppl 1():S29-34. PubMed ID: 3103640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.
    Mannucci PM; Brettler DB; Aledort LM; Lusher JM; Abildgaard CF; Schwartz RS; Hurst D
    Blood; 1994 Apr; 83(7):1958-62. PubMed ID: 7908234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological status and HIV antibodies in patients with haemophilia--a longitudinal study.
    Fuchs D; Hausen A; Reibnegger G; Werner ER; Vinazzer H; Dierich MP; Wachter H
    Wien Klin Wochenschr; 1988 Aug; 100(15):505-9. PubMed ID: 3140497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.